Genentech R&D Combining Diagnostics With Drugs Throughout The Portfolio
This article was originally published in The Pink Sheet Daily
Executive Summary
Avastin is one example where the drug’s mechanism of action may be too broad to warrant a companion diagnostic, CEO Levinson says.
You may also be interested in...
New FDA Policy On Diagnostics Studies “Fills A Big Gap,” CDRH Chief Says
The guidance “is intended to describe some statistically appropriate practices for reporting results from different studies evaluating diagnostic tests and identify some common inappropriate practices,” FDA states in the document.
NDAs Should Include More Cross-Study Analysis, FDA Says In Draft Guidance
FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications
New Look At Ezetimibe Fails To Confirm Vytorin Cancer Signal
Interim data from SHARP and IMPROVE-IT trials fail to show evidence of impact on cancer rates.